KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash from Investing Activities (2016 - 2025)

Nektar Therapeutics has reported Cash from Investing Activities over the past 16 years, most recently at $372000.0 for Q4 2025.

  • Quarterly results put Cash from Investing Activities at $372000.0 for Q4 2025, down 99.38% from a year ago — trailing twelve months through Dec 2025 was -$1.2 million (down 100.84% YoY), and the annual figure for FY2025 was -$1.2 million, down 100.84%.
  • Cash from Investing Activities for Q4 2025 was $372000.0 at Nektar Therapeutics, up from -$94.9 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for NKTR hit a ceiling of $130.3 million in Q1 2022 and a floor of -$94.9 million in Q3 2025.
  • Median Cash from Investing Activities over the past 5 years was $42.1 million (2023), compared with a mean of $42.5 million.
  • Biggest five-year swings in Cash from Investing Activities: surged 13521.08% in 2022 and later tumbled 305.73% in 2025.
  • Nektar Therapeutics' Cash from Investing Activities stood at $120.2 million in 2021, then tumbled by 66.71% to $40.0 million in 2022, then tumbled by 56.56% to $17.4 million in 2023, then skyrocketed by 246.4% to $60.2 million in 2024, then crashed by 99.38% to $372000.0 in 2025.
  • The last three reported values for Cash from Investing Activities were $372000.0 (Q4 2025), -$94.9 million (Q3 2025), and $49.6 million (Q2 2025) per Business Quant data.